• Je něco špatně v tomto záznamu ?

Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues

Z Svoboda, J Kvetina, G Kunesova, J Herink, J Bajgar, L Bartosova, P Zivny, V Palicka

. 2006 ; (27 Suppl 2) : 183-186.

Jazyk angličtina Země Švédsko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13029442

Grantová podpora
NR7935 MZ0 CEP - Centrální evidence projektů

OBJECTIVES: The alkaloid galantamine (GAL), which exhibits a combined anticholinesterase and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases. We attempted to achieve pharmacologically-induced enhancement of the parasympathomimetic activity of GAL in the key areas of rat brain, using an interactive combination of the alkaloid with the transmembrane enhancer L-carnitine (CAR). METHODS: We investigated activities of acetylcholinesterase (AChE) in brain areas (frontal cortex, basal ganglia, septum and hippocampus) and the hypophysis, and that of butyrylcholinesterase (BuChE) in plasma and liver. RESULTS: Following administration of the highest of the GAL doses used (2.5; 5; 10 mg/kg i.m.), AChE activity decreased mainly in the frontal cortex, hippocampus and hypophysis. In the interaction of GAL and CAR, AChE inhibition was stronger but without any statistical significance. The peripheral inhibition of BuChE was found to be dose-dependent. Premedication by CAR led to a slight change in the values of the activities monitored. CONCLUSIONS: CAR in terms of positive modulation of GAL targeting to the central nervous system had no statistically significant effect.

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc13029442
003      
CZ-PrNML
005      
20190104125138.0
007      
ta
008      
130913s2006 sw d f 000 0|eng||
009      
AR
035    __
$a (PubMed)17159811
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a sw
100    1_
$a Svoboda, Zbyněk $7 xx0081965 $u Institute of Experimental Biopharmaceutics, Joint Research Centre of Czech Academy of Sciences and PRO.MED.CS Praha a.s., Hradec Králové, Czech Republic
245    10
$a Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues / $c Z Svoboda, J Kvetina, G Kunesova, J Herink, J Bajgar, L Bartosova, P Zivny, V Palicka
504    __
$a Literatura
520    9_
$a OBJECTIVES: The alkaloid galantamine (GAL), which exhibits a combined anticholinesterase and direct parasympathomimetic mechanism of action, is employed in conjunction with therapeutic interventions in the stimulation of central cholinergic transfer in cognitive diseases. We attempted to achieve pharmacologically-induced enhancement of the parasympathomimetic activity of GAL in the key areas of rat brain, using an interactive combination of the alkaloid with the transmembrane enhancer L-carnitine (CAR). METHODS: We investigated activities of acetylcholinesterase (AChE) in brain areas (frontal cortex, basal ganglia, septum and hippocampus) and the hypophysis, and that of butyrylcholinesterase (BuChE) in plasma and liver. RESULTS: Following administration of the highest of the GAL doses used (2.5; 5; 10 mg/kg i.m.), AChE activity decreased mainly in the frontal cortex, hippocampus and hypophysis. In the interaction of GAL and CAR, AChE inhibition was stronger but without any statistical significance. The peripheral inhibition of BuChE was found to be dose-dependent. Premedication by CAR led to a slight change in the values of the activities monitored. CONCLUSIONS: CAR in terms of positive modulation of GAL targeting to the central nervous system had no statistically significant effect.
590    __
$a bohemika - dle Pubmed
650    02
$a acetylcholinesterasa $x krev $x metabolismus $7 D000110
650    02
$a zvířata $7 D000818
650    12
$a mozek $x enzymologie $x účinky léků $7 D001921
650    02
$a butyrylcholinesterasa $x krev $x metabolismus $7 D002091
650    12
$a karnitin $x farmakologie $7 D002331
650    02
$a cholinesterasové inhibitory $x farmakologie $7 D002800
650    12
$a galantamin $x farmakologie $7 D005702
650    02
$a játra $x enzymologie $x účinky léků $7 D008099
650    02
$a mužské pohlaví $7 D008297
650    02
$a hypofýza $x enzymologie $x účinky léků $7 D010902
650    02
$a krysa rodu Rattus $7 D051381
650    02
$a potkani Wistar $7 D017208
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Květina, Jaroslav, $d 1930- $7 jk01071205 $u Institute of Experimental Biopharmaceutics, Joint Research Centre of Czech Academy of Sciences and PRO.MED.CS Praha a.s., Hradec Králové, Czech Republic
700    1_
$a Krejčová, Gabriela $7 xx0035227 $u Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
700    1_
$a Herink, Josef, $d 1942- $7 jx20040423003 $u Institute of Experimental Biopharmaceutics, Joint Research Centre of Czech Academy of Sciences and PRO.MED.CS Praha a.s., Hradec Králové, Czech Republic
700    1_
$a Bajgar, Jiří, $d 1944- $7 js20020122033 $u Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
700    1_
$a Bartošová, Lucie, $d 1977- $7 xx0041840 $u Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
700    1_
$a Živný, Pavel, $d 1961- $7 mzk2006324255 $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Hospital of Charles University, Prague, Czech Republic
700    1_
$a Palička, Vladimír, $d 1946- $7 jn99240000830 $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Hospital of Charles University, Prague, Czech Republic
773    0_
$t Neuro-endocrinology letters $x 0172-780X $g č. 27 Suppl 2 (2006), s. 183-186 $p Neuroendocrinol Lett $w MED00168352
773    0_
$p Neuroendocrinol Lett $g 27 Suppl 2:183-6, 2006 Dec $x 0172-780X
910    __
$a ABA008 $b B 2520 $y 3 $z 0
990    __
$a 20130913110553 $b ABA008
991    __
$a 20190104125334 $b ABA008
999    __
$a ok $b bmc $g 993511 $s 827879
BAS    __
$a 3
BMC    __
$a 2006 $c 27 Suppl 2 $d 183-186 $i 0172-780X $m Neuro-endocrinology letters $x MED00168352 $n Neuro-endocrinol. lett.
GRA    __
$a NR7935 $p MZ0
LZP    __
$a 2013-09/dpbo

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...